New shot aims to tame hepatitis b in early human trial
NCT ID NCT07511218
First seen Apr 18, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This early-stage study tests a new injection called AHB-171 in 110 people, first in healthy volunteers and then in those with chronic hepatitis B. The main goals are to check safety and how the body processes the drug, with a first look at whether it can help control the virus. Participants must be 18–55 years old and meet specific health criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AusperBio Investigational Site
Ch’ang-ch’un, Jilin, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.